MUCUS-PENETRATING BUDESONIDE NANOSUSPENSION ENEMA FOR THE LOCAL TREATMENT OF INFLAMMATORY BOWEL DISEASE

Case ID:
C14902
Disclosure Date:
7/14/2017
Description:
Unmet Need:
Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis (UC), affects over a million individuals in the United States and has no known cure. Individuals are most frequently diagnosed between the ages of 15 and 35 and require a lifetime of disease management. Characterized by varying degrees of inflammation in the gastrointestinal tract, the administration of corticosteroids is the agreed upon first line of treatment for individuals with IBD. These steroids, which include prednisolone, prednisone, and budesonide, are administered based on their ability to bind to glucocorticoid receptors in inflammatory cells to reduce inflammation without significantly effecting salt balance in the body. While effective treatment exists, the delivery of corticosteroids could be improved as the colorectal mucus mesh traps and removes foreign particles like corticosteroids. Improved delivery mechanisms of corticosteroids, like budesonide, could therefore lead to better treatment outcomes and the mitigation of its side effects through the more efficient delivery of steroids to the inflamed area.       
 
Technology Overview:
Johns Hopkins researchers have begun to develop a new drug delivery system for the administration of budesonide via enema. Based on past research, Hopkins researchers had identified the use of nano-particles with muco-inert coatings (NS) as a possibly more effective delivery mechanism of steroids into the colorectal mucus mesh than current macron-sized delivery mechanisms (MS). Efficacy studies in mice with TNBS-induced colitis showed that, compared to untreated controls or budesonide MS enema, budesonide NS enema treatment resulted in significant amelioration of the macroscopic (decreased colon weight and ratio of colon to body weight) and microscopic (histology score) symptoms of IBD. Flow cytometric analysis of mice treated with budesonide MS versus budesonide NS enema showed that only budesonide NS enemas led to the reduction of the aboslute number of inflammatory macrophages.
 
Stage of Development:
The inventors have shown that budenoside NS enemas more effectively reduces the imflammation of the gastroinestinal tract than traditional mechanisms of corticosteroid delivery in mice.
 
Publications:
Maisel et. al. JCR (2015).
 
Patent Information:
Title App Type Country Serial No. Patent No. File Date Issued Date Expire Date Patent Status
MUCUS-PENETRATING BUDESONIDE NANOSUSPENSION ENEMA FOR THE LOCAL TREATMENT OF INFLAMMATORY BOWEL DISEASE ORD: Ordinary Utility United States 16/036,819 7/16/2018     Pending
Inventors:
Category(s):
For Information, Contact:
Sonriza Ford
sford23@jhu.edu
410-614-0300
Save This Technology:
2017 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum